Durvalumab is a medication used in this trial to help the body’s immune system fight cancer. It works by blocking a protein that stops the immune system from attacking cancer cells, allowing the immune system to better target and destroy them.

Tremelimumab is another medication in the trial that helps boost the immune system’s response against cancer. It works by targeting a specific protein that can suppress the immune system, thereby enhancing the body’s ability to fight cancer cells.

Oleclumab is included in the trial to target and block a protein that is involved in the growth and spread of cancer cells. By inhibiting this protein, the medication aims to slow down or stop the progression of the cancer.

Monalizumab is used in the trial to enhance the immune system’s ability to attack cancer cells. It works by blocking a protein that can inhibit immune responses, thus promoting a stronger attack on the cancer by the body’s natural defenses.

Non-small Cell Lung Cancer – This is a type of lung cancer that includes several subtypes such as squamous cell carcinoma, adenocarcinoma, and large cell carcinoma. It is called “non-small cell” to distinguish it from small cell lung cancer, which behaves differently. In early stages, the cancer is typically confined to the lungs and may not cause noticeable symptoms. As it progresses, it can spread to nearby tissues and lymph nodes. The disease is often detected through imaging tests when symptoms like persistent cough, chest pain, or shortness of breath appear. Early-stage non-small cell lung cancer is considered resectable, meaning it can potentially be removed through surgery.